巴瑞替尼联合外用糖皮质激素治疗中重度特应性皮炎:随机临床试验
BREEZE-AD7 是一项双盲、安慰剂对照 3 期随机临床试验,纳入 329 例对 TCS 应答不佳的中重度 AD 成人患者,随机接受巴瑞替尼 4 mg、2 mg 或安慰剂联合背景 TCS 治疗 16 周。结果显示 4 mg 组达到 vIGA-AD 0/1 的比例显著高于安慰剂组,安全性与此前研究一致。
要点
- 巴瑞替尼 4 mg 联合 TCS 可显著提高第 16 周 vIGA-AD 0/1 达标率。
- 4 mg 组治疗中出现不良事件比例高于安慰剂组,严重不良事件比例相似。
核心结论
- 巴瑞替尼 4 mg 联合背景 TCS 治疗可显著改善中重度 AD 的体征和症状,安全性与此前巴瑞替尼治疗 AD 的研究一致。
研究设计与样本
- 双盲、安慰剂对照 3 期随机临床试验 BREEZE-AD7,于 2018 年 11 月 16 日至 2019 年 8 月 22 日在亚洲、澳大利亚、欧洲和南美洲 10 个国家 68 个中心开展。
- 纳入 18 岁及以上、中重度 AD 且对 TCS 应答不佳的患者,随机 1:1:1 接受巴瑞替尼 2 mg(n=109)、4 mg(n=111)或安慰剂(n=109)每日一次治疗 16 周,允许使用低至中效 TCS。
主要发现
- 第 16 周达到 vIGA-AD 0(清除)或 1(几乎清除)且较基线改善≥2 分的比例:4 mg 组 34 例(31%),2 mg 组 26 例(24%),安慰剂组 16 例(15%)。
- 治疗中出现不良事件:4 mg 组 64/111 例(58%),2 mg 组 61/109 例(56%),安慰剂组 41/108 例(38%)。
- 严重不良事件:4 mg 组 4 例(4%),2 mg 组 2 例(2%),安慰剂组 4 例(4%);最常见不良事件为鼻咽炎、上呼吸道感染和毛囊炎。
关键数值与推荐
- 主要终点为第 16 周 vIGA-AD 评分 0(清除)或 1(几乎清除)且较基线改善≥2 分的患者比例。
临床怎么用
- 对 TCS 应答不佳的中重度 AD 成人患者,可考虑巴瑞替尼 4 mg 每日一次联合背景 TCS 治疗。
- 治疗期间需关注不良事件,常见鼻咽炎、上呼吸道感染和毛囊炎,严重不良事件发生率与安慰剂相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced disease severity in moderate to severe atopic dermatitis (AD) in 2 phase 3 monotherapy studies. OBJECTIVE: To assess the efficacy and safety of 4 mg and 2 mg of baricitinib in combination with background topical corticosteroid (TCS) therapy in adults with moderate to severe AD who previously had an inadequate response to TCS therapy. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled, phase 3 randomized clinical trial, BREEZE-AD7 (Study of Baricitinib [LY3009104] in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis) was conducted from November 16, 2018, to August 22, 2019, at 68 centers across 10 countries in Asia, Australia, Europe, and South America. Patients 18 years or older with moderate to severe AD and an inadequate response to TCSs were included. After completing the study, patients were followed up for up to 4 weeks or enrolled in a long-term extension study. INTERVENTIONS: Patients were randomly assigned (1:1:1) to receive 2 mg of baricitinib once daily (n = 109), 4 mg of baricitinib once daily (n = 111), or placebo (n = 109) for 16 weeks. The use of low-to-moderate potency TCSs was allowed. MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients achieving a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 0 (clear) or 1 (almost clear), with a 2-point or greater improvement from baseline at week 16. RESULTS: Among 329 patients (mean [SD] age, 33.8 [12.4] years; 216 [66%] male), at week 16, a vIGA-AD score of 0 (clear) or 1 (almost clear) was achieved by 34 patients (31%) receiving 4 mg of baricitinib and 26 (24%) receiving 2 mg of baricitinib compared with 16 (15%) receiving placebo (odds ratio vs placebo, 2.8 [95% CI, 1.4-5.6]; P = .004 for the 4-mg group; 1.9 [95% CI, 0.9-3.9]; P = .08 for the 2-mg group). Treatment-emergent adverse events were reported in 64 of 111 patients (58%) in the 4-mg group, 61 of 109 patients (56%) in the 2-mg group, and 41 of 108 patients (38%) in the placebo group. Serious adverse events were reported in 4 patients (4%) in the 4-mg group, 2 (2%) in the 2-mg group, and 4 (4%) in the placebo group. The most common adverse events were nasopharyngitis, upper respiratory tract infections, and folliculitis. CONCLUSIONS AND RELEVANCE: A dose of 4 mg of baricitinib in combination with background TCS therapy significantly improved the signs and symptoms of moderate to severe AD, with a safety profile consistent with previous studies of baricitinib in AD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03733301.
引用
- Reich K, Kabashima K, Peris K, et al. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020. PMID: 33001140. doi:10.1001/jamadermatol.2020.3260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。